Search

Your search keyword '"Bieber, Katja"' showing total 290 results
Start Over Author "Bieber, Katja" Publication Year Range Last 10 years
290 results on '"Bieber, Katja"'

3. High throughput screening identifies repurposable drugs for modulation of innate and acquired immune responses

Author

Ghorbanalipoor, Saeedeh, Matsumoto, Kazuko, Gross, Natalie, Heimberg, Linda, Krause, Malin, Veldkamp, Wendelien, Magens, Moritz, Zanken, Johannes, Neuschutz, Kerstin J., De Luca, David A., Kridin, Khalaf, Vidarsson, Gestur, Chakievska, Lenche, Visser, Remco, Kunzel, Sven, Recke, Andreas, Gupta, Yask, Boch, Katharina, Vorobyev, Artem, Kalies, Kathrin, Manz, Rudolf A., Bieber, Katja, and Ludwig, Ralf J.

Published
2024
Full Text
View/download PDF

4. C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement

Author

Liu, Fei, Ryan, Sarah T., Fahnoe, Kelly C., Morgan, Jennifer G., Cheung, Anne E., Storek, Michael J., Best, Alejandro, Chen, Hui A., Locatelli, Monica, Xu, Shuyun, Schmidt, Enno, Schmidt-Jiménez, Leon F., Bieber, Katja, Henderson, Joel M., Lian, Christine G., Verschoor, Admar, Ludwig, Ralf J., Benigni, Ariela, Remuzzi, Giuseppe, Salant, David J., Kalled, Susan L., Thurman, Joshua M., Holers, V. Michael, Violette, Shelia M., and Wawersik, Stefan

Published
2024
Full Text
View/download PDF

7. Autoimmune pre-disease

Author

Bieber, Katja, Hundt, Jennifer E., Yu, Xinhua, Ehlers, Marc, Petersen, Frank, Karsten, Christian M., Köhl, Jörg, Kridin, Khalaf, Kalies, Kathrin, Kasprick, Anika, Goletz, Stephanie, Humrich, Jens Y., Manz, Rudolf A., Künstner, Axel, Hammers, Christoph M., Akbarzadeh, Reza, Busch, Hauke, Sadik, Christian D., Lange, Tanja, Grasshoff, Hanna, Hackel, Alexander M., Erdmann, Jeanette, König, Inke, Raasch, Walter, Becker, Mareike, Kerstein-Stähle, Anja, Lamprecht, Peter, Riemekasten, Gabriela, Schmidt, Enno, and Ludwig, Ralf J.

Published
2023
Full Text
View/download PDF

11. IgG Fc N-Glycosylation Translates MHCII Haplotype into Autoimmune Skin Disease

Author

Clauder, Ann-Katrin, Kordowski, Anna, Bartsch, Yannic C., Köhl, Gabriele, Lilienthal, Gina-Maria, Almeida, Larissa N., Lindemann, Timo, Petry, Janina, Rau, Christina N., Gramalla-Schmitz, Anna, Dühring, Lara, Elbracht, Claudia, Kenno, Samyr, Tillmann, Jenny, Wuhrer, Manfred, Ludwig, Ralf J., Ibrahim, Saleh M., Bieber, Katja, Köhl, Jörg, Ehlers, Marc, and Manz, Rudolf Armin

Published
2021
Full Text
View/download PDF

12. Dexamethasone's Clinical Efficacy in Experimental Autoimmune Pancreatitis Correlates with a Unique Transcriptomic Signature, Whilst Kinase Inhibitors Are Not Effective.

Author

Agrifoglio, Ottavia, Kasprick, Anika, Gross, Natalie, Wahlig, Marc, Kauffold, Emilia, Woitas, Aline, Vorobyev, Artem, Ehlers, Luise, Ludwig, Ralf J., Bieber, Katja, and Jaster, Robert

Subjects
GENE expression profiling, PRINCIPAL components analysis, KINASE inhibitors, RNA sequencing, DRUG target
Abstract

(1) Background: Autoimmune pancreatitis (AIP) is mainly treated with steroids. Using an AIP mouse model, we investigated two potential alternatives, the transforming growth factor-β-activated kinase 1 inhibitor, takinib, and the Janus kinase inhibitor, tofacitinib. (2) Methods: In a multicenter preclinical study, MRL/MpJ mice were injected with polyinosinic/polycytidylic acid (poly I:C) for two weeks to induce AIP. They were then treated for four weeks with either takinib (25, 50, or 75 mg/kg body weight), tofacitinib (5, 10 or 15 mg/kg), dexamethasone (1 mg/kg), or solvent, while the poly I:C injections were continued. The severity of AIP was assessed histopathologically. Flow cytometry was used to examine lymphocyte subtypes in the spleen and mesenteric lymph nodes. The pancreatic gene expression profiles were analyzed by RNA sequencing. (3) Results: Poly I:C-treated mice developed severe AIP with inflammation, destruction of acinar tissue, and fibrosis. Dexamethasone significantly attenuated the disease, while takinib or tofacitinib had no effects. Dexamethasone also antagonized the effects of poly I:C on the relative frequencies of the AIP-associated lymphocyte subtypes CD4/CD69, CD8/CD44high, and CD4/CD25/FoxP3 in the spleen. In the principal component analysis of pancreatic transcriptomics, poly I:C-injected mice treated with tofacitinib, takinib, or solvent clustered together, while untreated and dexamethasone-treated mice formed separate, unique clusters. (4) Conclusions: Dexamethasone effectively reduced AIP severity, while takinib and tofacitinib were ineffective. The unique gene expression profile in dexamethasone-treated mice may provide a basis for identifying new drug targets for AIP treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Risk of death, major adverse cardiac events and relapse in patients with bullous pemphigoid treated with systemic or topical corticosteroids.

Author

Kridin, Khalaf, Bieber, Katja, Vorobyev, Artem, Moderegger, Eva Lotta, Hernandez, Gema, Schmidt, Enno, and Ludwig, Ralf J

Subjects
*MAJOR adverse cardiovascular events, *TOPICAL drug administration, *CLOBETASOL, *BULLOUS pemphigoid, *PROPENSITY score matching
Abstract

Background According to current guidelines, systemic or topical corticosteroids are both recommended as first-line treatments for bullous pemphigoid (BP). There is evidence to suggest that topical application may be associated with a lower risk of mortality. However, there is a lack of comprehensive large-scale data comparing mortality rates, as well as the risk of major adverse cardiac events (MACE), infections and relapse, between systemic and topical corticosteroid treatments. Objectives To evaluate the risk of death, MACE, infections and relapse in patients with BP treated with systemic or topical corticosteroids. Methods A population-based retrospective cohort study was performed using the TriNetX US Collaborative Network. As a measure against bias, propensity score matching for age, sex, 10 diseases and 6 medications was done, and 3 sensitivity analyses were conducted. Results All-time risk of death was increased in US patients with BP exposed to any dose of systemic corticosteroids (n = 2917) vs. patients treated with topical clobetasol propionate [ n = 2932; hazard ratio (HR) 1.43, 95% confidence interval (CI) 1.28–1.58 (P < 0.001)]. This was consistent in time-stratified analysis (1- and 3-year mortality rates) and in analysis contrasting prednisone (equivalent) doses of 1–10 mg (low) or 30–100 mg (medium–high) systemic corticosteroid to topical treatment. The increased risk of death in US patients with BP exposed to any dose of systemic corticosteroids vs. topical treatment was accompanied by increased risks for MACE (HR 1.33, 95% CI 1.08–1.64; P = 0.008) and infections (HR 1.33, 95% CI 1.15–1.54; P < 0.001). The risk of continued disease or relapse was decreased in patients treated with systemic vs. topical corticosteroids (HR 0.85, 95% CI 0.77–0.94; P = 0.002). Results regarding mortality and continued disease or relapse persisted in three sensitivity analyses. Potential limitations included the retrospective data collection, bias for treatment selection and miscoding. Conclusions Pending validation in prospective studies, where feasible – and despite the heightened risk of relapse – topical corticosteroid treatment may be advantageous over systemic corticosteroid treatment owing to its significantly lower risk of death. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. C-type lectin receptor expression is a hallmark of neutrophils infiltrating the skin in epidermolysis bullosa acquisita

Author

Guerrero-Juarez, Christian F., primary, Schilf, Paul, additional, Li, Jing, additional, Zappia, Maria Paula, additional, Bao, Lei, additional, Patel, Payal M., additional, Gieseler-Tillmann, Jenny, additional, Murthy, Sripriya, additional, Cole, Connor, additional, Sverdlov, Maria, additional, Frolov, Maxim V., additional, Hashimoto, Takashi, additional, Ishii, Norito, additional, Rülicke, Thomas, additional, Bieber, Katja, additional, Ludwig, Ralf J., additional, Sadik, Christian D., additional, and Amber, Kyle T., additional

Published
2023
Full Text
View/download PDF

24. 183 Exploring the role of C5aR2 in neutrophil-driven autoimmune diseases: An often overlooked player in the pathogenesis of epidermolysis bullosa acquisita

Author

Seiler, Daniel, primary, Kleingarn, Marie, additional, Kähler, Katja, additional, Freiwald, Tilo, additional, Bibby, Jack, additional, Gruner, Caroline, additional, Schanzenbacher, Jovan, additional, Ehlers-Jeske, Elvira, additional, Kenno, Samyr, additional, Sadik, Christian, additional, Schmidt, Enno, additional, Bieber, Katja, additional, Afzali, Behdad, additional, Köhl, Jörg, additional, Ludwig, Ralf, additional, Kemper, Claudia, additional, and Karsten, Christian, additional

Published
2023
Full Text
View/download PDF

25. The Leukotriene B4 and its Receptor BLT1 Act as Critical Drivers of Neutrophil Recruitment in Murine Bullous Pemphigoid-Like Epidermolysis Bullosa Acquisita

Author

Sezin, Tanya, Krajewski, Matthias, Wutkowski, Adam, Mousavi, Sadegh, Chakievska, Lenche, Bieber, Katja, Ludwig, Ralf J., Dahlke, Markus, Rades, Dirk, Schulze, Franziska S., Schmidt, Enno, Kalies, Kathrin, Gupta, Yask, Schilf, Paul, Ibrahim, Saleh M., König, Peter, Schwudke, Dominik, Zillikens, Detlef, and Sadik, Christian D.

Published
2017
Full Text
View/download PDF

28. Forward genetics and functional analysis highlight Itga11 as a modulator of murine psoriasiform dermatitis

Author

Bieber, Katja, primary, Bezdek, Siegfried, additional, Gupta, Yask, additional, Vorobyev, Artem, additional, Sezin, Tanya, additional, Gross, Natalie, additional, Prüssmann, Jasper, additional, Sayegh, Jean‐Paul, additional, Becker, Mareike, additional, Mousavi, Sadegh, additional, Hdnah, Ashref, additional, Künzel, Sven, additional, Ibrahim, Saleh M, additional, Ludwig, Ralf J, additional, Gullberg, Donald, additional, and Sadik, Christian D, additional

Published
2023
Full Text
View/download PDF

32. Gene-diet interactions associated with complex trait variation in an advanced intercross outbred mouse line

Author

Vorobyev, Artem, Gupta, Yask, Sezin, Tanya, Koga, Hiroshi, Bartsch, Yannic C., Belheouane, Meriem, Künzel, Sven, Sina, Christian, Schilf, Paul, Körber-Ahrens, Heiko, Beltsiou, Foteini, Lara Ernst, Anna, Khil’chenko, Stanislav, Al-Aasam, Hassanin, Manz, Rudolf A., Diehl, Sandra, Steinhaus, Moritz, Jascholt, Joanna, Kouki, Phillip, Boehncke, Wolf-Henning, Mayadas, Tanya N., Zillikens, Detlef, Sadik, Christian D., Nishi, Hiroshi, Ehlers, Marc, Möller, Steffen, Bieber, Katja, Baines, John F., Ibrahim, Saleh M., and Ludwig, Ralf J.

Published
2019
Full Text
View/download PDF

33. Bullous pemphigoid induced by IgG targeting type XVII collagen non‐NC16A/NC15A extracellular domains is driven by Fc gamma receptor‐ and complement‐mediated effector mechanisms and is ameliorated by neonatal Fc receptor blockade.

Author

Pigors, Manuela, Patzelt, Sabrina, Reichhelm, Niklas, Dworschak, Jenny, Khil'chenko, Stanislav, Emtenani, Shirin, Bieber, Katja, Hofrichter, Maxi, Kamaguchi, Mayumi, Goletz, Stephanie, Köhl, Gabriele, Köhl, Jörg, Komorowski, Lars, Probst, Christian, Vanderheyden, Katrien, Balbino, Bianca, Ludwig, Ralf J, Verheesen, Peter, and Schmidt, Enno

Subjects
FC receptors, BULLOUS pemphigoid, COLLAGEN, BASAL lamina, SKIN inflammation, LABORATORY mice
Abstract

Bullous pemphigoid (BP) is an autoimmune blistering disease characterized by autoantibodies targeting type XVII collagen (Col17) with the noncollagenous 16A (NC16A) ectodomain representing the immunodominant site. The role of additional extracellular targets of Col17 outside NC16A has not been unequivocally demonstrated. In this study, we showed that Col17 ectodomain‐reactive patient sera depleted in NC16A IgG induced dermal–epidermal separation in a cryosection model indicating the pathogenic potential of anti‐Col17 non‐NC16A extracellular IgG. Moreover, injection of IgG targeting the murine Col17 NC14–1 domains (downstream of NC15A, the murine homologue of human NC16A) into C57BL/6J mice resulted in erythematous skin lesions and erosions. Clinical findings were accompanied by IgG/C3 deposits along the basement membrane and subepidermal blistering with inflammatory infiltrates. Disease development was significantly reduced in either Fc‐gamma receptor (FcγR)‐ or complement‐5a receptor‐1 (C5aR1)‐deficient mice. Inhibition of the neonatal FcR (FcRn), an atypical FcγR regulating IgG homeostasis, with the murine Fc fragment IgG2c‐ABDEG, a derivative of efgartigimod, reduced anti‐NC14–1 IgG levels, resulting in ameliorated skin inflammation compared with isotype‐treated controls. These data demonstrate that the pathogenic effects of IgG targeting the Col17 domain outside human NC16A/murine NC15A are partly attributable to antibody‐mediated FcγR‐ and C5aR1 effector mechanisms while pharmacological inhibition of the FcRn represents a promising treatment for BP. The mouse model of BP will be instrumental in further investigating the role of Col17 non‐NC16A/NC15A extracellular epitopes and validating new therapies for this disease. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Lichen sclerosus: The 2023 update

Author

De Luca, David A., primary, Papara, Cristian, additional, Vorobyev, Artem, additional, Staiger, Hernán, additional, Bieber, Katja, additional, Thaçi, Diamant, additional, and Ludwig, Ralf J., additional

Published
2023
Full Text
View/download PDF

36. Morphea: The 2023 update

Author

Papara, Cristian, primary, De Luca, David A., additional, Bieber, Katja, additional, Vorobyev, Artem, additional, and Ludwig, Ralf J., additional

Published
2023
Full Text
View/download PDF

39. Distinct Metabolite Profile in Pemphigus Vulgaris

Author

Boch, Katharina, primary, Sharma, Arunabh, additional, Folberth, Julica, additional, Zillikens, Detlef, additional, Schmidt, Enno, additional, Bieber, Katja, additional, Schwaninger, Markus, additional, Ludwig, Ralf J., additional, and Dempfle, Astrid, additional

Published
2022
Full Text
View/download PDF

40. Luteolin peracetate and gossypolone inhibit immune complex-mediated neutrophil activation in vitro and dermal-epidermal separation in an ex vivo model of epidermolysis bullosa acquisita.

Author

Kai Yang, Junping Yin, Xiaoyang Yue, Bieber, Katja, Riemekasten, Gabriela, Ludwig, Ralf J., Petersen, Frank, and Xinhua Yu

Subjects
EPIDERMOLYSIS bullosa, LUTEOLIN, NEUTROPHILS, IMMUNE complexes, NATURAL products
Abstract

Introduction: Natural products have been shown to an important source of therapeutics for human disease. In this study, we aimed to identify natural compounds as potential therapeutics for epidermolysis bullosa acquisita (EBA), an autoimmune disease caused by autoantibodies to type VII collagen (COL7). Methods: Utilizing an in vitro experimental system, we screened a natural product library composed of 800 pure compounds for their inhibitory effect on COL7-anti-COL7 IgG immune complex (IC)-mediated neutrophil activation and on neutrophil-mediated tissue damage. Results: Three natural compounds, namely luteolin peracetate, gossypol, and gossypolone were capable in inhibiting the IC-induced neutrophil adhesion and oxygen burst in vitro. Furthermore, luteolin peracetate and gossypolone were able to inhibit the anti-COL7 IgG induced dermal-epidermal separation in an ex vivo model for EBA. Discussion: In summary, this study demonstrates that luteolin peracetate and gossypolone are potential therapeutics for experimental EBA, which deserves further investigation. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. Corrigendum: Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases

Author

Ghorbanalipoor, Saeedeh, primary, Emtenani, Shirin, additional, Parker, Melissa, additional, Kamaguchi, Mayumi, additional, Osterloh, Colin, additional, Pigors, Manuela, additional, Gross, Natalie, additional, Khil’chenko, Stanislav, additional, Kasprick, Anika, additional, Patzelt, Sabrina, additional, Wortmann, Diana, additional, Ibrahim, Ibrahim O., additional, Izumi, Kentaro, additional, Goletz, Stephanie, additional, Boch, Katharina, additional, Kalies, Kathrin, additional, Bieber, Katja, additional, Smith, Paul, additional, Schmidt, Enno, additional, and Ludwig, Ralf J., additional

Published
2022
Full Text
View/download PDF

43. Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases

Author

Ghorbanalipoor, Saeedeh, primary, Emtenani, Shirin, additional, Parker, Melissa, additional, Kamaguchi, Mayumi, additional, Osterloh, Colin, additional, Pigors, Manuela, additional, Gross, Natalie, additional, Khil’chenko, Stanislav, additional, Kasprick, Anika, additional, Patzelt, Sabrina, additional, Wortmann, Diana, additional, Ibrahim, Ibrahim O., additional, Izumi, Kentaro, additional, Goletz, Stephanie, additional, Boch, Katharina, additional, Kalies, Kathrin, additional, Bieber, Katja, additional, Smith, Paul, additional, Schmidt, Enno, additional, and Ludwig, Ralf J., additional

Published
2022
Full Text
View/download PDF

50. The relevance of complement in pemphigoid diseases: A critical appraisal

Author

Papara, Cristian, primary, Karsten, Christian M., additional, Ujiie, Hideyuki, additional, Schmidt, Enno, additional, Schmidt-Jiménez, Leon F., additional, Baican, Adrian, additional, Freire, Patricia C., additional, Izumi, Kentaro, additional, Bieber, Katja, additional, Peipp, Matthias, additional, Verschoor, Admar, additional, Ludwig, Ralf J., additional, Köhl, Jörg, additional, Zillikens, Detlef, additional, and Hammers, Christoph M., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results